TLR7/8 dual-agonist EIK1001 plus pembrolizumab and chemotherapy in first-line, stage 4 non-small cell lung cancer (NSCLC) demonstrates durable effect in combination with standard-of-care, and a tolerability pro of systemic administration in an outpatient setting With median follow-up of 12.7 months, objective response rate (ORR) for the squamous cohort was 72% and disease control rate (DCR) was 100%, with a median duration of response of 12.9 months and multiple participants continuing in active

Median overall survival of 12 months with RBS2418 monotherapy in subjects with heavily pretreated tumors that express ENPP1 and cGAS proteins (TME-EG+ phenotype), versus 4.2 months in subjects whose tumors do not (median 3 prior systemic therapies; p=0.0022) Median overall survival of 14 months in heavily pretreated TME-EG+ late-line metastatic colorectal cancer (mCRC, median 4 prior systemic therapies), including subjects with liver metastases Well tolerated, with no treatment-related serious a

With RAS-targeted therapies gaining ground in pancreatic cancer, Incyte is advancing its own contender. On Monday, the company shared what it called "encouraging" early data for its experimental KRAS G12D inhibitor INCB161734, along with two new partnerships, including one with Bristol Myers Squibb, to test the drug in separate combos against the disease. Phase I findings, presented at the European Society for Medical Oncology (ESMO) congress, showed the oral drug produced an objective response

Divarasib monotherapy demonstrated superior efficacy over first-generation KRAS G12C inhibitors, lowering the risk of disease progression or death by 42% and the overall risk of death by 44%, in the phase III Krascendo 1 study1,2 At the time of primary analysis, divarasib achieved a median overall survival of approximately 18 months, compared to 12 months for sotorasib or adagrasib1,2 No new safety signals were observed with divarasib; the most common treatment-related adverse events were mainly

Pfizer scored a green light from the FDA on Monday to move its prostate cancer combination up earlier in the treatment paradigm. The US regulator approved PARP inhibitor Talzenna (talazoparib) plus androgen receptor pathway inhibitor Xtandi (enzalutamide) for patients with homologous recombination repair (HRR) gene-mutated metastatic hormone-sensitive prostate cancer (mHSPC), also known as androgen pathway modulation-naïve or -sensitive disease. The regulatory nod expands the regimen's label, i

Oct. 26, 2026 -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced that a New Indication Application for sintilimab in combination with Nolgileucel injection (GC101) has been accepted for review by the China National Medical Products Administration (NMPA). The application is proposed to be sin

The first NMPA-approved anti-FcRn therapy to complete its full clinical development for gMG patients in China Oct. 22, 2026 -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced that the National Medical Products Administration (NMPA) of China has approved the Biologics License Application (BLA) for batoclimab injection (subcutaneous inj

EVX-01 induced an immune response in all patients in the trial with 89% of the vaccine neoantigens generating potent specific T-cell responses Three-year data from the EVX-01 phase 2 trial in patients with advanced melanoma to be presented at the ESMO 2026 Congress supplementing very convincing two-year data from the trial The data will be presented at a poster session on October 24, 2026, followed by a webinar on October 29, 2026, providing further insights into the findings October 23, 2026

In a 1L EGFR atypical population with more than double the rate of baseline CNS metastases as competitor datasets, enozertinib demonstrates a potential best-in-class 84% confirmed systemic ORR and 70% confirmed intracranial ORR, with multiple intracranial complete responses 88% 6-month landmark PFS compares favorably to current standards of care and to investigational therapies; follow-up ongoing with majority of patients continuing on treatment Competitive safety pro no significant off-target t

Gilead Sciences waded further into the immunology and inflammation (I&I) disease space on Thursday with the proposed purchase of PepStar Therapeutics' IL-23R inhibitor programme, which includes lead candidate HCXT-2001, in Phase I testing. The US drugmaker is splashing $1.28 billion in upfront cash to gain the asset, an oral macrocyclic peptide inhibitor of IL-23R with an extended half-life. The acquisition is expected to close this quarter. According to Gilead, IL-23R is a clinically validated